ImmunoCellular Therapeutics has named Helen Kim to its board of directors. She has also been elected as chairperson of the company’s product strategic committee. Kim currently serves on the board of directors at Sunesis Pharmaceuticals and as the chief business officer of NGM Biopharmaceuticals.

Kim recently served as chief program officer for the Gordon and Betty Moore Foundation. She also served as president and CEO of Kosan Biosciences.